Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
MOMETASON Mepha Nasenspray 50 mcg 140 Dos
Drug
Mometason-Mepha Nasenspray, Suspension
Rhinitis, Nasenpolypen
12.02.3. – nasal drugs with corticosteroids
HAM – Human medicine
NASSS – nasal spray, suspension
S – synthetic products for human use
B – Dispensed on prescription by a physician or veterinarian (B)
Z – approved
2/7/2014
12/31/9999
Dosage strength
Mometason-Mepha Nasenspray, Suspension
Rhinitis, Nasenpolypen
01
Z – approved
Package
7680632480017
In trade from / since 2/7/2014
A/R – Authorised / referenced
140 Single-dose(s)
001
Z – approved
Declaration
Component
50 µg mometasoni furoas
mometasoni furoas monohydricus
mometasoni furoas monohydricus
cellulosum microcristallinum et carmellosum natricum
glycerolum
polysorbatum 80
acidum citricum monohydricum
natrii citras dihydricus
20 µg benzalkonii chloridum
aqua ad iniectabile
glycerolum
polysorbatum 80
acidum citricum monohydricum
natrii citras dihydricus
20 µg benzalkonii chloridum
aqua ad iniectabile
Spezialitätenliste***
SL
-
-
17.65
None
No
10%
Yes
Authorisation holder
7601001396685
Mepha Pharma AG
Kirschgartenstrasse 14
4051 Basel (BS)
Kirschgartenstrasse 14
4051 Basel (BS)
Date of revision of the text
4/29/2025
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.